Government Bans 16 Fixed-Dose Combination (FDC) Drugs to Curb Health Risks

The Ministry of Health and Family Welfare has recently issued a notification banning 16 Fixed-Dose Combination (FDC) drugs. This regulatory intervention is part of the government's ongoing efforts to streamline the pharmaceutical landscape in India and ensure that only safe, efficacious, and scientifically validated medicines reach the public. An FDC drug consists of two or more active pharmaceutical ingredients combined in a single dosage form. While FDCs can improve patient compliance, the proliferation of irrational combinations—those lacking therapeutic justification—poses significant health risks, including adverse drug reactions and the exacerbation of antimicrobial resistance (AMR). This move is a continuation of the government's broader strategy to regulate the drug market, which has historically seen a high volume of unapproved or irrational combinations. The decision follows rigorous reviews by expert committees, including the Drugs Technical Advisory Board (DTAB), which evaluated the safety and efficacy profiles of these formulations. By removing these drugs from the market, the government aims to protect consumers from unnecessary exposure to multiple chemicals that offer no added clinical benefit. Furthermore, this policy aligns with global health standards, as the irrational use of antibiotics and other drugs in combination is a primary driver of AMR, a critical public health challenge that threatens the efficacy of modern medicine.